C14H18F3N3S, monoclinic, P2(1)/c (no. 14), a = 4.61919(4) angstrom, b = 29.1507(3) angstrom, c = 11.27803(10) angstrom, beta = 94.4768(8)degrees, V = 1513.99(3) angstrom(3), Z = 4, R- gt (F) = 0.0588, wR( ref )(F-2) = 0.1579, T = 160 K
C25H21N5OS, monoclinic, P21/n (no. 14), a = 12.9303(5) Å, b = 9.1111(4) Å, c = 18.7111(8) Å, β = 97....
In the cation of the title salt, C8H13N 4+·C4H3O4 -, the piperazinium ring adopts a slightly distor...
In the title compound, C19H20F2N2O, the six-membered piperazine group adopts a slightly distorted ch...
C14H18F3N3S, monoclinic, P2(1)/c (no. 14), a = 4.61919(4) angstrom, b = 29.1507(3) angstrom, c = 11....
C14H18F3N3S, monoclinic, P2(1)/c (no. 14), a = 4.61919(4) angstrom, b = 29.1507(3) angstrom, c = 11....
C20H22N4OS, triclinic, P (1) over bar (no. 2), a = 6.8528(3) angstrom, b = 11.3498(5) angstrom, c = ...
C20H22N4OS, triclinic, P (1) over bar (no. 2), a = 6.8528(3) angstrom, b = 11.3498(5) angstrom, c = ...
C20H22N4OS, triclinic, P (1) over bar (no. 2), a = 6.8528(3) angstrom, b = 11.3498(5) angstrom, c = ...
C20H22N4OS, triclinic, P (1) over bar (no. 2), a = 6.8528(3) angstrom, b = 11.3498(5) angstrom, c = ...
C14H12N4O3S, monoclinic, P21/n (no. 14), a = 12.2777(3) Å, b = 9.4312(2) Å, c = 12.9412(2) Å, β = 10...
C14H12N4O3S, monoclinic, P21/n (no. 14), a = 12.2777(3) Å, b = 9.4312(2) Å, c = 12.9412(2) Å, β = 10...
The title compound, C17H19F2N2+·C7H5O3−·C7H6O3, is a co-crystal from 4-[bis(4-fluorophenyl)methy...
The title compound, C12H18N4O2, crystallizes in the zwitterionic form with protonation at the N atom...
C13H10F3N3O4, triclinic, P (1) over bar (no. 2), a = 7.0524(14) angstrom, b = 7.8044(16) angstrom, c...
In the title compound, C6H17N32+center dot 2ClO(4)(-), the piperazine ring adopts a chair conformati...
C25H21N5OS, monoclinic, P21/n (no. 14), a = 12.9303(5) Å, b = 9.1111(4) Å, c = 18.7111(8) Å, β = 97....
In the cation of the title salt, C8H13N 4+·C4H3O4 -, the piperazinium ring adopts a slightly distor...
In the title compound, C19H20F2N2O, the six-membered piperazine group adopts a slightly distorted ch...
C14H18F3N3S, monoclinic, P2(1)/c (no. 14), a = 4.61919(4) angstrom, b = 29.1507(3) angstrom, c = 11....
C14H18F3N3S, monoclinic, P2(1)/c (no. 14), a = 4.61919(4) angstrom, b = 29.1507(3) angstrom, c = 11....
C20H22N4OS, triclinic, P (1) over bar (no. 2), a = 6.8528(3) angstrom, b = 11.3498(5) angstrom, c = ...
C20H22N4OS, triclinic, P (1) over bar (no. 2), a = 6.8528(3) angstrom, b = 11.3498(5) angstrom, c = ...
C20H22N4OS, triclinic, P (1) over bar (no. 2), a = 6.8528(3) angstrom, b = 11.3498(5) angstrom, c = ...
C20H22N4OS, triclinic, P (1) over bar (no. 2), a = 6.8528(3) angstrom, b = 11.3498(5) angstrom, c = ...
C14H12N4O3S, monoclinic, P21/n (no. 14), a = 12.2777(3) Å, b = 9.4312(2) Å, c = 12.9412(2) Å, β = 10...
C14H12N4O3S, monoclinic, P21/n (no. 14), a = 12.2777(3) Å, b = 9.4312(2) Å, c = 12.9412(2) Å, β = 10...
The title compound, C17H19F2N2+·C7H5O3−·C7H6O3, is a co-crystal from 4-[bis(4-fluorophenyl)methy...
The title compound, C12H18N4O2, crystallizes in the zwitterionic form with protonation at the N atom...
C13H10F3N3O4, triclinic, P (1) over bar (no. 2), a = 7.0524(14) angstrom, b = 7.8044(16) angstrom, c...
In the title compound, C6H17N32+center dot 2ClO(4)(-), the piperazine ring adopts a chair conformati...
C25H21N5OS, monoclinic, P21/n (no. 14), a = 12.9303(5) Å, b = 9.1111(4) Å, c = 18.7111(8) Å, β = 97....
In the cation of the title salt, C8H13N 4+·C4H3O4 -, the piperazinium ring adopts a slightly distor...
In the title compound, C19H20F2N2O, the six-membered piperazine group adopts a slightly distorted ch...